Insilico Medicine and Elevian form R&D partnership.
Biotech startup, Elevian, is focused on developing anti-aging medicines that target the growth differentiation factor 11 (GDF11) pathway. The company recently announced a collaboration with artificial intelligence developer Insilico Medicine to accelerate its development efforts.
Elevian is providing biological and structural target data. Insilico will use its generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies to identify potential small-molecule candidates. The work will involve both digital and physical screening of compounds in existing libraries. Promising molecules will then be synthesized by contract service provider WuXi AppTec, which has a history of collaboration with Insillico.
This deal is the second of its kind for Insilico in the last year. In August 2018, the company began a collaboration with the Buck Institute for Research on Aging and Napa Therapeutics, a spinout of Juvenescence, focused on nicotinamide adenine dinucleotide (NAD+) metabolism.
